Human embryonic stem cells: a potential source for cellular therapy.

Item

http://www.wikidata.org/entity/Q35661046

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Human embryonic stem cells: a potential source for cellular therapy.

@ast

Human embryonic stem cells: a potential source for cellular therapy.

@en

type

Item

label

Human embryonic stem cells: a potential source for cellular therapy.

@ast

Human embryonic stem cells: a potential source for cellular therapy.

@en

prefLabel

Human embryonic stem cells: a potential source for cellular therapy.

@ast

Human embryonic stem cells: a potential source for cellular therapy.

@en

P1476

Human embryonic stem cells: a potential source for cellular therapy.

@en

P2093

Joseph Itskovitz-Eldor

http://www.w3.org/2001/XMLSchema#string

Sharon Gerecht-Nir

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.

Prevention of cytomegalovirus disease in recipients of solid-organ transplants.

Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.

Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease.

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

P304

51-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-6135.2004.00727.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

4 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P50

Sharon Gerecht-Nir

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14871274

http://www.w3.org/2001/XMLSchema#string